[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022006500A - Terapia de combinacion que involucra compuestos macrociclicos de diarilo. - Google Patents

Terapia de combinacion que involucra compuestos macrociclicos de diarilo.

Info

Publication number
MX2022006500A
MX2022006500A MX2022006500A MX2022006500A MX2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A MX 2022006500 A MX2022006500 A MX 2022006500A
Authority
MX
Mexico
Prior art keywords
combination therapy
macrocyclic compounds
therapy involving
diaryl
diaryl macrocyclic
Prior art date
Application number
MX2022006500A
Other languages
English (en)
Inventor
Wei Deng
Dayong Zhai
Jingrong J Cui
Laura Rodon
Brion W Murray
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of MX2022006500A publication Critical patent/MX2022006500A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a los métodos y las composiciones utilizados para el tratamiento de cáncer con el macrociclo de diarilo en combinación con un inhibidor KRAS, tal como un inhibidor de KRAS G12C.
MX2022006500A 2019-11-27 2020-11-25 Terapia de combinacion que involucra compuestos macrociclicos de diarilo. MX2022006500A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962941026P 2019-11-27 2019-11-27
US202062981822P 2020-02-26 2020-02-26
US202063005681P 2020-04-06 2020-04-06
PCT/US2020/062390 WO2021108682A1 (en) 2019-11-27 2020-11-25 Combination therapy involving diaryl macrocyclic compounds

Publications (1)

Publication Number Publication Date
MX2022006500A true MX2022006500A (es) 2022-07-04

Family

ID=76129920

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006500A MX2022006500A (es) 2019-11-27 2020-11-25 Terapia de combinacion que involucra compuestos macrociclicos de diarilo.

Country Status (12)

Country Link
US (2) US11654145B2 (es)
EP (1) EP4065125A4 (es)
JP (1) JP2023505056A (es)
KR (1) KR20220133866A (es)
CN (1) CN114901286B (es)
AU (1) AU2020391222A1 (es)
BR (1) BR112022010278A2 (es)
CA (1) CA3162632A1 (es)
IL (1) IL293206A (es)
MX (1) MX2022006500A (es)
TW (1) TW202133855A (es)
WO (1) WO2021108682A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230103007A1 (en) * 2020-01-31 2023-03-30 Verastem, Inc. Combination therapy for treating abnormal cell growth
EP4308123A1 (en) * 2021-03-17 2024-01-24 Amgen Inc. Sotorasib dosing regimen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010319322A1 (en) * 2009-11-13 2012-05-31 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
SI3572416T1 (sl) * 2014-01-24 2023-02-28 Turning Point Therapeutics, Inc. Diarilni makrocikli kot modulatorji protein kinaz
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
WO2017007759A1 (en) * 2015-07-06 2017-01-12 Tp Therapeutics, Inc. Diaryl macrocycle polymorph
TN2019000271A1 (en) * 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US20190134056A1 (en) * 2017-03-10 2019-05-09 The Trustees Of The Stevens Institute Of Technolog K-ras mutations and antagonists
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
AU2018369759B2 (en) 2017-11-15 2022-11-24 Array Biopharma Inc. KRas G12C inhibitors
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11603374B2 (en) * 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3849534A4 (en) * 2018-09-10 2022-06-22 Mirati Therapeutics, Inc. COMBINATION THERAPIES
CN110256421A (zh) * 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
US11666574B2 (en) * 2019-11-27 2023-06-06 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Also Published As

Publication number Publication date
KR20220133866A (ko) 2022-10-05
CN114901286B (zh) 2024-05-10
EP4065125A1 (en) 2022-10-05
US20240033266A1 (en) 2024-02-01
WO2021108682A1 (en) 2021-06-03
US11654145B2 (en) 2023-05-23
CN114901286A (zh) 2022-08-12
TW202133855A (zh) 2021-09-16
BR112022010278A2 (pt) 2022-10-04
JP2023505056A (ja) 2023-02-08
US20210220364A1 (en) 2021-07-22
IL293206A (en) 2022-07-01
AU2020391222A1 (en) 2022-06-30
EP4065125A4 (en) 2024-01-03
CA3162632A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2020012261A (es) Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2022004656A (es) Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
PH12019501328A1 (en) 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors
MX2023010430A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
MX2021007790A (es) Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
MY196830A (en) Kras g12c inhibitors and methods of using the same
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
AU2018238202A8 (en) Combination therapy for the treatment or prevention of tumours
MX2022006366A (es) Terapia de combinacion que implica compuestos de diarilo macrociclico.
MX2023011856A (es) Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.
AU2011274510A8 (en) Combinations of kinase inhibitors for the treatment of cancer
MX2024005228A (es) Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras).
MX2022010977A (es) Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.
MX2022010975A (es) Inhibidores de egfr, kras, braf y otras dianas y uso de estos.
MX2024008551A (es) Terapias de combinacion.
MX2024007673A (es) Inhibidores de poli adp-ribosa polimerasas (parp1).
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.